Personalizing immunotherapy so patients can fight their own disease.
Argos is focused on the treatment of metastatic cancers and chronic infections using a proprietary platform technology that stimulates immune cells with messenger RNA. The company’s lead product is for the personalized treatment of advanced renal cell carcinoma and is in phase III clinical development. A second product for therapeutic vaccination in HIV is in phase II development. Argos has also developed an interferon-neutralizing antibody for systemic lupus and has developed a CD83 Soluble Protein for Transplant Rejection/ Autoimmune Disorders in late preclinical development. Argos is listed on Nasdaq and traded under the symbol ARGS.
- CEO Jeff Abbey
- Industry Biotech